Leukemia & Lymphoma Society Allocates $5 Million for Enhanced Clinical Trial Access

Leukemia & Lymphoma Society Invests in Clinical Trial Access



The Leukemia & Lymphoma Society (LLS) has made a significant commitment to cancer research by investing nearly $5 million through its Equity in Access Research Program. This initiative aims to enhance access and participation in clinical trials, especially among communities historically underrepresented in such vital research. Clinical trials are often the beacon of hope for patients seeking advanced treatment options and quality cancer care, yet barriers continue to hinder participation for many.

Addressing Underrepresentation in Clinical Trials



Despite the critical nature of clinical trials in the fight against cancer, participation rates from certain demographic groups remain alarmingly low. Data indicates that groups such as minorities, the economically disadvantaged, and veterans face systemic challenges that deter them from joining these essential studies. The lack of representation can lead to treatment gaps, where solutions that may benefit a broader patient population remain unexplored.

According to Dr. Eric Cooks, Senior Director of the Equity in Access Research Program at LLS, “Novel treatments available through clinical trials have the potential to lead to better outcomes for cancer patients, but lack of access and underrepresentation continue to constrain progress.”

The funds will support health services researchers who are exploring interventions to tackle these issues head-on. By identifying and addressing barriers in clinical trial accessibility, LLS endeavors to create an environment where all cancer patients have equal opportunities to participate in groundbreaking research.

The Current Research Cohort



The latest grants under LLS's program will support two major research teams:

1. Durham VA Health Care System: Led by Dr. Daphne Friedman and Dr. Leah Zullig, this study aims to enhance participation in therapeutic clinical trials for veterans with blood cancers across 12 Veterans Administration (VA) facilities. Their research will not only expand the trial offerings but also implement innovative patient support systems like a trial navigation process that aids coordinators in identifying suitable participants.

2. Dana-Farber Cancer Institute: Dr. Andrew Hantel, along with Dr. Christopher Lathan and Dr. Richard Stone, will focus on developing strategies to foster participation among historically underrepresented groups, specifically those marginalized by race, ethnicity, or socioeconomic status. They will investigate methods to lower barriers in trial design and enhance collaboration between academic institutions and community care providers.

Importance of Research and Funding



Since 2021, LLS has allocated nearly $18 million to support various health services research studies aimed at reducing disparities in cancer care. The continuous engagement and funding from organizations like Royalty Pharma and AstraZeneca exemplify a collective effort to promote equity in health care.

The findings emerging from these research studies promise to inform both LLS’s strategic approach and broader healthcare policy. The insights gained will not only address immediate barriers but will also cultivate a culture of inclusivity and accessibility in cancer research.

A Future Without Blood Cancer



With over 75 years of dedicated work, LLS stands at the forefront of blood cancer research and patient support. Their mission remains unwavering: to cure blood cancer and improve the quality of life for patients and their families. As they advance their Equity in Access program, LLS continues to advocate for systemic change that prioritizes patient empowerment and equal opportunities in clinical trials.

For more details on LLS and its initiatives, visit www.LLS.org or contact their Information Resource Center at (800) 955-4572, available Monday through Friday from 9 AM to 9 PM ET.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.